anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain the subject composition for a topical use, capable of treating wrinkles and fine wrinkles, effectively stiffening skin tissue and subcutaneous tissue and further recovering skin brightness by including a dehydroepiandrosterone sulfate. SOLUTION: This composition contains 0.001-0.5 wt.% based on the total weight of a dehydroepiandrosterone sulfate (e.g. dehydroisoandrosterone=3- sodium sulfate or the like). Preferably the composition further contains one or more activators (e.g. 5-n-octanoylsalicylic acid or the like) selected from an α-hydroxy acid, a β-hydroxy acid, an α-keto acid, etc., and one or more hormones (e.g. estrone or the like) selected from a natural and a synthetic estrogenic progesterone-like and androgen-like hormones.
This is a phase I/IIa, national, open label, single arm, interventional study examining safety and tolerability for the ipilimumab/UV1 combination in patients with unresectable or metastatic malignant melanoma. Patients that have signed the informed consent form will be asked to take part in the study. All patients will receive ipilimumab together with the UV1 vaccine and rranulocyte-macrophage colony-stimulating factor (GM-CSF). Ipilimumab will be given every 3rd week for a total of 4 doses. The UV1 vaccine and GM-CSF will be given before and between treatments of ipilimumab. The maximum number of UV1/GM-CSF will be 10 doses.

Immunoresponders maybe followed up every third months for 5 years after the first UV1 treatment. Follow-up is onging.
Few studies have examined how epidural placement changes localized sensation at the epidural insertion site. This study will be the first study to quantitatively measure sensation at the epidural insertion site. The investigator will assess localized pressure sensitivity with an algometer. An algometer is a hand-held device commonly used by neurologist to detect sensory deficits and measures the pressure sensitivity threshold in a 1-cm diameter circular area. Ultrasound (US) pre-procedural examination provides more accurate landmarks for the placement of epidural catheters. The investigator will determine if an US examination prior to epidural placement reduces localized pressure sensitivity. The investigator will also determine if there are correlations between the participants characteristics and/or comorbidities and increased pressure sensitivity at the insertion site.
To provide shampoo compositions which are excellent in transparency and handleability while improving combability.SOLUTION: The shampoo composition contains water, dispersed particles dispersed in water, a nonionic surfactant, and an anionic surfactant. The dispersed particles contain silicone with no added alkylene oxide. The average particle size of the dispersed particles is 500 nm or less. The amount of the dispersed particles is 0.2 mass% or more and 3.0 mass% or less based on the total mass of the shampoo composition. The shampoo composition contains, as a nonionic surfactant, one or more alkylene oxide-added compounds selected from alkylene oxide adducts of fatty acid esters and polyoxyalkylene alkyl ether. The HLB value of the alkylene oxide-added compound is 14.0 or more. The amount of the alkylene oxide-added compound is 0.5% by mass or more based on the total mass of the shampoo composition.SELECTED DRAWING: None
Twice daily oral administration. 15, 30 or 45 mg morphine sulfate capsules. Dosage 30 to 150 mg per day.
The purpose of this study is to evaluate the safety and performance of the EYEMATE system in patients undergoing concomitant implantation of a BKPro type 1 and an EYEMATE sensor over the 24 months period beginning at implantation. The EYEMATE system involves an EYEMATE implantable sensor working together with a MESOGRAPH hand-held reading device. The aim of this investigation is to collect intraocular pressure data with the EYEMATE pressure sensor in patients with BKPRO type and determine the relationship between the following glaucoma characteristics: intraocular pressure, characteristics and evolution of the optic nerve, visual fields, and OCT of the optic nerve. The intraocular pressure will be measured by three means. First, there will be mapping of the diurnal fluctuation of IOP with daily IOP self-measurement profiles with the EYEMATE system (subjects). Secondly, there will be mapping of fluctuation of IOP measurements with the EYEMATE system (site staff). Thirdly, the IOP will be evaluated through the measurement of the Schiotz tonometer on the limbal conjunctiva.

The primary performance objective is to collect IOP data with the EYEMATE system and compare the level of agreement between IOP measurements made using schiotz tonometry and the EYEMATE system over the first 24 months following implantation. The secondary performance objective is to determine the relationship between the IOP data with the use of the EYEMATE system and the progression of glaucoma through the evaluation of the characteristics of the optic nerve, visual fields, and OCT of the peripapillary retinal nerve fiber layers in patients with BKPRO type 1. The secondary safety objective is to evaluate the safety and tolerability of the EYEMATE pressure sensor, record adverse effects and incidence of device deficiencies in the first 24 months through the recording of incidence, nature, seriousness, severity and duration of adverse events at day 1 and at months 1, 4, 8, 12, 16, 20, 24 following implantation of the EYEMATE pressure sensor.
This is a Phase 2a, randomized, double-blind, placebo-controlled, 14-day repeat oral, dose ranging study to determine the safety, PK and PD effects of SP-304 in patients with chronic idiopathic constipation. Patients diagnosed with chronic idiopathic constipation (CIC) will be screened for the anticipated 4 cohorts, to yield 80 randomized patients for enrollment. Four dose cohorts are planned (0.3 mg, 1.0 mg, 3.0mg, and 9.0 mg) with 20 patients per dose cohort \[randomization ratio 3:1 (15 receive SP-304:5 receive placebo)\]. Patients who continue to meet all the entry criteria and complete the pre-treatment bowel movement (BM) diary will receive, in a double-blind, randomized fashion, SP-304 or matching placebo. It is expected that each patient will complete all 14 days of dosing (including making accurate BM diary entries for all 14 days in the treatment period). All patients receiving at least one dose of SP-304 or matching placebo will be considered evaluable for the safety endpoints. If a patient receives at least 5 doses per treatment week (1 dose per day for 7 days) and has completed BM diary entries for those 5 dosing days in each corresponding treatment week, he/she will be considered evaluable.
The Unwinding Anxiety program focuses on teaching individuals 1) to understand how anxious worry is developed and perpetuated through reinforcement learning, 2) how to recognize these worry "habit loops" and 3) how to bring mindful awareness to moments of worry such that they can uncouple feelings of anxiety from reactive worry thinking and "ride out" habitual mind states that perpetuate and reinforce anxiety. Together, these help individuals "unlearn"/extinguish worry at a core mechanistic level.
The abnormal deposition and intercellular propagation of disease-specific protein play a central role in the pathogenesis of many neurodegenerative disorders. Recent studies share the common observation that the formation of protein oligomers and subsequent pathological filaments is an essential step for the disease. Synucleinopathies such as Parkinson's disease (PD), dementia with Lewy bodies (DLB) or multiple system atrophy (MSA) are neurodegenerative diseases characterized by the aggregation of the α-synucleinprotein in neurons and/or in oligodendrocytes (glial cytoplasmic inclusions), neuronal loss, and astrogliosis. A similar mechanism of protein Tau-dependent neurodegeneration is a major feature of tauopathies, represented by Alzheimer's disease (AD), corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), and Pick's disease (PD). The specific inhibition of the protein misfolding and their interneuronal spreading represents a promising therapeutic strategy against both disease pathology and progression. The most recent research focuses on finding potential applications targeting the pathological forms of proteins responsible for neurodegeneration. This review highlights the mechanisms relevant to protein-dependent neurodegeneration based on the most common disorders and describes current therapeutic approaches targeting protein misfolding and aggregation.
Pheochromocytoma and paraganglioma (PPGL) represent a group of rare neuroendocrine tumors known for their potential to metastasize. This study provides a comprehensive retrospective evaluation of 15 patients diagnosed with metastatic or recurrent PPGL at our institution over a two-decade span (2000-2020). Our primary objectives were to delineate the long-term clinical outcomes and pinpoint key prognostic determinants. Median duration from initial PPGL diagnosis to the onset of metastasis or recurrence stood at 5.8 years. Predominant sites for metastasis included the bone, lung, lymph nodes, and peritoneum. A salient finding was that surgical interventions targeting metastatic lesions significantly improved prognosis. Further analysis revealed that a Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) exceeding 7 closely associated with unfavorable outcomes. These insights not only underscore the clinical variability of PPGL's progression but also highlight the pivotal role of surgical management for metastatic or recurrent cases. The value of the PASS score as an informative prognostic tool was evident, suggesting its utility in shaping future therapeutic approaches. Given the intricacies of PPGL, collaborative studies involving larger patient cohorts will be crucial to optimize management strategies and prognostication.
Erlotinib, a kinase inhibitor, is a quinazolinamine with the chemical name N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine. Erlotinib tablet contains erlotinib as the hydrochloride salt that has the following structural formula:  


Erlotinib hydrochloride has the molecular formula C22H23N3O4.HCl and a molecular weight of 429.9. The molecule has a pKa of 5.42 at 25°C. It is freely soluble in formic acid, very slightly soluble in N,N-Dimethyl formamide and practically insoluble in water.

Erlotinib tablets for oral administration are available in three dosage strengths containing erlotinib hydrochloride (27.3 mg, 109.3 mg and 163.9 mg) equivalent to 25 mg, 100 mg and 150 mg erlotinib and the following inactive ingredients: lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, magnesium stearate and sodium lauryl sulfate. The film-coat inactive ingredients are hypromellose, hydroxypropyl cellulose, titanium dioxide and polyethylene glycol 400.
A time release dispenser of insect repellant and anchored to the stratum corneum, whereby the repellant cargo is dispensed over a period of time, and resists removal by perspiration, abrasion, or detergent wash. An example is a bipolar lipid membrane formed into liposome configuration, and caused to envelope and partition an organic molecule that normally has a very limited solubility in aqueous media. The organic molecule may be, for example, a mosquito repellant N, N-Diethyl-m-toluamide known by the acronym "DEET". Another example is an insecticide ar repellant for animals. The prior art liposomal delivery system depends upon forming liposomes in an aqueous media, thereby capturing some of the media in the core volume. In the preferred embodiment this invention, a burden of a substantially water insoluble substance is sequestered in a bipolar lipid bladder, which lipid and burden may be used as such or targeted to a designated site. Preferably, a target molecule, such as pyridinethione, is used to anchor the liposomal structure to the stratum corneum:
The initial dose of diltiazem hydrochloride injection should be 0.25 mg/kg actual body weight as a bolus administered over 2 minutes (20 mg is a reasonable dose for the average patient). If response is inadequate, a second dose may be administered after 15 minutes. The second bolus dose of diltiazem hydrochloride injection should be 0.35 mg/kg actual body weight administered over 2 minutes (25 mg is a reasonable dose for the average patient). Subsequent intravenous bolus doses should be individualized for each patient. Patients with low body weights should be dosed on a mg/kg basis. Some patients may respond to an initial dose of 0.15 mg/kg, although duration of action may be shorter. Experience with this dose is limited.
Post isometric relaxation with participants using 20% of their maximum voluntary contraction will be given to global muscles of core commonly involved in primary dysmenorrhea glutus maximus, Illiopsoas and pirifirmis. Post isometric contraction will be held for 6 to 10 seconds followed by 15 o 30 seconds stretch, rst time will be 5 seconds in between repetations and number of repetations will be 3-5.
PROBLEM TO BE SOLVED: To obtain a new protein composed of a metalloprotease having a specific amino acid sequence and useful for the treatment, prevention, etc., of diseases such as diabetic nephropathy, glomerular nephritis, pulmonary fibrosis, hepatic fibrosis, hepatic cirrhosis, marble bone disease and herniated disk. SOLUTION: This new protein (salt) is composed of a metalloprotease having an amino acid sequence the same as or essentially the same as the amino acid sequence of the formula. The metalloprotease or its DNA is useful e.g. as an agent for the treatment and prevention of various diseases such as diabetic nephropathy, glomerular nephritis, pulmonary fibrosis, hepatic fibrosis, hepatic cirrhosis, marble bone disease and herniated disk and the protein is useful e.g. for the screening of a compound promoting or inhibiting the protease activity. The protein is produced by cloning a cDNA having a new base sequence from a cDNA library originated from human liver and expressing a matrix metalloprotease which has been found to be a protein for which the cDNA codes.
PURPOSE: An antibacterial composition containing Dianthus chinenesis extract is provided to enhance antibacterial activity against Streptococcus mutans and to suppress the generation of organic acid by Streptococcus mutans. CONSTITUTION: An antibacterial composition for suppressing oral bacteria contains 0.01-20 parts by weight of Dianthus chinenesis extract as an active ingredient. The oral bacteria includes Streptococcus mutans. The composition is manufactured in the form of a mouth cleanser, toothpaste, oral spray, or denture cleaning agent. A composition for preventing or treating dental caries and periodontal disorders contains 0.01-20 parts by weight of the extract as an active ingredient. The composition is manufactured in the form of gum, candy, jelly, chocolate, mouth cleanser, oral spray, or toothpaste.
Background Early diagnosis of dementia benefits both patient and caregiver. Nevertheless, dementia in primary care is currently under-diagnosed in developed countries. In several countries educational interventions were developed to improve dementia diagnosis and management in primary care. Some of these interventions were successful in increasing the number of dementia diagnoses and in changing attitudes and knowledge of health care staff. However, none of these interventions focussed on collaboration between GPs and nurses in dementia care. We developed a Dementia Training Program (DTP) aimed at stimulating collaboration in dementia primary care. We expect it to increase the number of cognitive assessments and dementia diagnoses, as well as to improve attitudes and knowledge of GPs and nurses.

Methods/Design The DTP is a complex educational intervention and consists of 2 workshops, a coaching program, and case-based consultations either face-to-face or by phone or e-mail, access to an internet forum, and a Computerized Clinical Decision Support System on dementia diagnostics and management. 100 duos of GPs and nurses will be recruited, from which 2/3 will be allocated to the intervention group and 1/3 to the control group. The effects of implementation of the DTP will be studied in an assessor blinded cluster-randomised controlled trial. Primary outcomes are the number of cognitive assessments and dementia diagnosis in a period of 9 months, starting after workshop participation of the duos. Secondary outcomes are measured on GP and nurse level: rate of adherence to national guidelines for dementia diagnosis, attitude, confidence and knowledge regarding dementia diagnosis and management; on patient level: number of emergency calls, visits and consultations and patient satisfaction; and on caregiver level: informal caregiver burden and satisfaction. Data will be collected from GPs' electronic medical dossiers, self registration forms and questionnaires. Statistical analysis will be performed by using MANOVA-method. Also, exploratory analyses will be performed, in order to gain insight into barriers and facilitators for implementation and the causal relations between the rate of success of the intervention components and the outcomes.
The invention discloses a medicament for external use for treating onychomycosis. Raw material components are dried, the material mixing is performed according to the mixture ratio, the raw material components are evenly mixed and ground, and the powder is sieved and blended into paste by a moistening blender to obtain a finished product. The raw material components comprise the following materials by weight portion: 3 to 5 portions of nux vomica, 1 to 3 portions of alum, 2 to 3 portions of borneol, 2 to 3 portions of glossy ganoderma powder, 2 to 3 portions of griseofulvin tablets, 1 to 3 portions of sulfur, and 1 to 3 portions of semen aesculi. The moistening blender is lactic acid. The medicament has the advantages of short treatment time, no pain during the treatment, convenient treatment, high therapeutic effect, few pharmaceutical components and the like. The medicament can treat and eradicate refractory thymion caused by viruses such as verrucae, voix pedis and the like.
Methods and utensils are provided for administering plant extract(s) at controlled amount via smoking, as well as for providing complexes of honey and plant extracts. Plant extract(s) may be used in utensils that are inserted into a smoking appliance, and have indications of the compounds and/or characteristics of the plant extract. Upon smoking the smoking appliance, the plant extracts may be inhaled in pre-defined amounts. Using plant extracts in such way enables standardization of amounts and components thereof, and may be particularly applicable to cannabis oils. Furthermore, complexes of honey and plant extracts may be provided by letting bees step on or be soiled by plant extracts on their way into the beehive, causing them to incorporate the plant extracts into the honey preparation process. Resulting complexes may be a preferable and particularly beneficial way of administering plant extracts, e.g., cannabis extracts.
PURPOSE:To obtain dietary fiber, excellent in safety and useful for health, etc., according to simple operation by adding water to wheat flour, kneading the mixture, washing the resultant dough, etc., with water, separating water- insoluble gluten, etc., adding water to the separated residue, carrying out centrifuging treatment and drying the prepared white emulsion. CONSTITUTION:Water is added to wheat flour and the resultant mixture is kneaded to produce a dough or an emulsion, which is then washed with water to separate water-insoluble gluten. The remaining starch-containing emulsion is simultaneously recovered to separate the starch from the starch-containing emulsion. Water is further added to the separated residue to prepare an emulsion diluted with water. The prepared emulsion diluted with water is then subjected to centrifuging treatment and separated into respective two of a colored solid substance and a white emulsion or three of the colored solid substance, the white emulsion and water. The part of the white emulsion is subsequently dried to afford the objective dietary fiber.
Participants will be randomized to start induction with 4 or 6 ampoules of gonadotropins from day 2 till the day of human chorionic gonadotropin (HCG), dose adjusted according to ovarian response monitored by serum E2 and ultrasound evaluation. All patients were followed up by TVUS scan daily or on alternate days according to the ovarian response to treatment starting on treatment cycle day 6 for folliculometry and endometrial thickness and pattern. Cetrotide (MerckSerono, Germany) 0.25 subcutaneously will be added when the leading follicle (DF) reaches \>12 mm and HCG 10 000 IU intramuscularly (Pregnyl, Merck Sharp, United Kingdom)will be given only if we have at least 3 mature follicles \>14 mm and the leading one \>17 mm; then, ovum pickup (OPU) was done after 36 hours of HCG and metaphase II ocytes were analyzed. The intracytoplasmic sperm injection (ICSI) procedure will be performed in all cases to avoid low fertilization rate by conventional IVF. Fertilization was assessed 16 to 18 hours after ICSI, and embryo quality will be evaluated 2 and 3 days after ICSI according to the number of blastomeres and the degree of fragmentation and multinucleation. Oocytes were collected and embryos will be cultured in ISM1 culture medium (Origiomedicult media, Denmark). Transfer of cleaving embryos will be done on day 3 after oocyte retrieval (using Labotect semirigid catheter; labotect GmbH, Germany), when the woman has at least 1 embryo (GI) otherwise canceled embryo transfer (ET). The ET was done by 1 person in each center. Both of the transferring consultants have more than 5 years experience in IVF unit. . All patients will receive luteal support in the form of daily progesterone cyclogest (Actavis, United Kingdom) 800 mg daily starting from day of ovum retrieval till day of hCG testing. Serum b hCG level was assessed on day 14 after ET and considered positive if \>5 mIU/ml. The TVUS was performed 28 days after ET to confirm ongoing pregnancy by visualization of intrauterine sac.
Autoimmune inner ear disease (AIED) is an organ-specific disease characterized by irreversible, prolonged, and progressive hearing and equilibrium dysfunctions. The primary symptoms of AIED include asymmetric sensorineural hearing loss accompanied by vertigo, aural fullness, and tinnitus. AIED is divided into primary and secondary types. Research has been conducted using animal models of rheumatoid arthritis (RA), a cause of secondary AIED. However, current models are insufficient to accurately analyze vestibular function, and the mechanism underlying the onset of AIED has not yet been fully elucidated. Elucidation of the mechanism of AIED onset is urgently needed to develop effective treatments. In the present study, we analyzed the pathogenesis of vertigo in autoimmune diseases using a mouse model of type II collagen-induced RA. Auditory brain stem response analysis demonstrated that the RA mouse models exhibited hearing loss, which is the primary symptom of AIED. In addition, our vestibulo-oculomotor reflex analysis, which is an excellent vestibular function test, accurately captured vertigo symptoms in the RA mouse models. Moreover, our results revealed that the cause of hearing loss and vestibular dysfunction was not endolymphatic hydrops, but rather structural destruction of the organ of Corti and the lateral semicircular canal ampulla due to an autoimmune reaction against type II collagen. Overall, we were able to establish a mouse model of AIED without endolymphatic hydrops. Our findings will help elucidate the mechanisms of hearing loss and vertigo associated with AIED and facilitate the development of new therapeutic methods.